Insulin glulisine
Also known as: Apidra, Glulisine, HMR 1964, INS-GLU, Insulin glulisine, Insulin glulisine rDNA
Source Insulin glulisine at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Insulin glulisine (brand Apidra) is a synthetic insulin analog with rapid onset and short duration, used to control postprandial hyperglycemia in diabetes mellitus.
Mechanism of Action
Binds to the insulin receptor, activating downstream signaling to increase glucose uptake and inhibit hepatic glucose production.
Routes of Administration
Goals & Uses
- Type 1 diabetes managementEndocrine/metabolicHigh
- Type 2 diabetes managementEndocrine / MetabolicHigh
- HbA1c reductionGlycemic ManagementHigh
- Glycemic controlDiabetesHigh
- Continuous subcutaneous insulin infusion (CSII)Delivery OptimizationModerate
- Postprandial glucose controlGlycemic ManagementHigh
Contraindications
- Severe insulin resistanceMetabolicModerate
- Hypersensitivity to insulin glulisine or excipientsImmunologicHigh
- HypoglycemiaMetabolicHigh
Adverse Effects
- EdemaFluid BalanceUncommonSwelling from fluid retention
- HypokalemiaElectrolyteUncommon
- HypoglycemiaMetabolicCommonAbnormally low blood glucose
- Allergic reactionsImmunologicalRare
- Injection site reactionsLocalUncommon
- Weight gainMetabolicCommonIncrease in body weight
Drug Interactions
- Beta-adrenergic blockersModerate
- Thiazolidinediones (e.g., pioglitazone)Moderate
- Concurrent use of other insulin productsHigh
- Beta-blockersModerate
- AlcoholModerate
- Sympathomimetics (e.g., epinephrine, salbutamol)Moderate
- CorticosteroidsModerate
- ACE inhibitorsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Renal impairmentOrgan ImpairmentRelative
- Elderly patientsAgeRelative
- Pediatric patients under 4 yearsAgeRelative
- Pediatric patients (<2 years)AgeAbsolute
Regulatory Status
- European UnionApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusEMA approval for rapid-acting insulin therapy.
- United StatesApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusFDA approved 2004.
- United KingdomApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusMHRA approval; same as EU.
Approved for subcutaneous administration in type 1 and type 2 diabetes; not interchangeable with other insulin products without dose adjustment.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Insulin glulisine?
Insulin glulisine (brand Apidra) is a synthetic insulin analog with rapid onset and short duration, used to control postprandial hyperglycemia in diabetes mellitus.
What is Insulin glulisine used for?
Insulin glulisine is educationally associated with: Type 1 diabetes management, Type 2 diabetes management, HbA1c reduction, Glycemic control, Continuous subcutaneous insulin infusion (CSII), Postprandial glucose control. Educational only — not medical advice.
How is Insulin glulisine administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Insulin glulisine?
Reported adverse effects include: Edema, Hypokalemia, Hypoglycemia, Allergic reactions, Injection site reactions, Weight gain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Insulin glulisine?
Recorded contraindications: Severe insulin resistance, Hypersensitivity to insulin glulisine or excipients, Hypoglycemia. Consult a qualified clinician before use.